Ligand Pharmaceuticals Inc. has entered into global license and supply agreements with Novartis for the development and commercialization of a Captisol-enabled oral liquid formulation of trametinib, a kinase inhibitor indicated as a single agent or in combination with dabrafenib, for the treatment of unresectable or metastatic melanoma with BRAF V600 mutation. Ligand will be eligible to receive a license fee and royalties, and revenue from Captisol material sales. Novartis will be responsible fo...